Case Study: PeriFlow Therapeutics achieves a review-ready Phase 1 design in two weeks with AIRA Health

PeriFlow Therapeutics reaches review-ready Phase 1 design in 2 weeks with AIRA Health

PeriFlow Therapeutics, a Boston-based biotech company, faced the expensive and slow traditional path of clinical trial design. Getting a Phase 1 study design and protocol review-ready typically required hiring expensive external experts, costing $500K–$1.5M and taking 3–8 months. PeriFlow turned to AIRA Health to find a more efficient solution.

AIRA Health provided a platform that integrated clinical development strategy, study design, and protocol drafting into one workflow. Using AIRA, PeriFlow reached a review-ready Phase 1 design in two weeks and a first protocol draft in just two days. This approach cost up to 90% less than the traditional path and helped the company avoid costly, avoidable amendments by catching design flaws early.

PeriFlow Therapeutics